Claudine Isaacs, MD, discusses the rapidly evolving HER2-positive breast cancer armamentarium.
Claudine Isaacs, MD, professor, medical director, Fisher Center for Familial Cancer Research, co-director, Breast Cancer Program, Lombardi Comprehensive Cancer Center at Georgetown University, discusses the rapidly evolving HER2-positive breast cancer armamentarium.
In recent years, significant advances have been made across breast cancer subtypes, says Isaacs. The field of HER2-positive breast cancer, in particular, has gained a number of regulatory approvals.
For example, the phase 2 HER2CLIMB trial randomized patients with HER2-positive metastatic breast cancer who were previously treated with trastuzumab (Herceptin), pertuzumab (Perjeta), and ado-trastuzumab emtansine (T-DM1; Kadcyla) to receive tucatinib (Tukysa) or placebo, in combination with trastuzumab and capecitabine.
Data from HER2CLIMB showed prolonged progression-free survival and overall survival with the tucatinib-based regimen versus placebo, says Isaacs.
These findings led to the April 2020 approval of tucatinib in combination with trastuzumab/capecitabine for the treatment of patients with unresectable locally advanced or metastatic HER2-positive breast cancer, Isaacs concludes.